Pfizer Inc. (PFE)
Pre-Market:
| Previous Close | 51.34 |
| Open | 51.22 |
| Bid | 50.05 x 2200 |
| Ask | 50.29 x 800 |
| Day's Range | 50.16 - 51.42 |
| 52 Week Range | 38.48 - 61.71 |
| Volume | |
| Avg. Volume | 28,174,531 |
| Market Cap | 282.889B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | 14.40 |
| EPS (TTM) | 3.50 |
| Earnings Date | May 02, 2022 - May 06, 2022 |
| Forward Dividend & Yield | 1.60 (3.21%) |
| Ex-Dividend Date | May 12, 2022 |
| 1y Target Est | 59.33 |
- Reuters
REFILE-U.S. to study whether longer Paxlovid course needed to combat reinfections
The U.S. National Institutes of Health is in talks with Pfizer Inc about studying whether a longer course of the drugmaker's COVID-19 antiviral treatment Paxlovid is needed to prevent reinfections, top U.S. infectious diseases expert Dr. Anthony Fauci said on Wednesday. "We're going to be planning what studies we're going to be doing relatively soon, within the next few days" in order to determine whether or not a longer course is needed, Fauci said during a White House COVID-19 briefing. Some patients have reported that COVID symptoms recurred after completing the five-day course of treatment and experiencing improvement, but exactly how many have experienced such a rebound is unclear.
- Motley Fool
Why Pfizer Looks Better Than Moderna as a Long-Term Buy
For a stock to be a strong long-term buy, investors need to have confidence that its business will be able to grow indefinitely. Both Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are examples of companies that continue to thrive today due to the pandemic with their highly successful COVID-19 vaccines generating billions in sales for their respective companies. COVID-19 revenue has resulted in surging revenue for Pfizer.
